Domov › Chronická lymfocytová leukémia › Michigan
Klinické štúdie Chronická lymfocytová leukémia v štáte Michigan
12 štúdií pre Chronická lymfocytová leukémia hľadá účastníkov v zariadeniach v štáte Michigan.
Mestá v štáte Michigan
- Detroit7 štúdií
- Grand Rapids5 štúdií
- Lansing3 štúdií
- Livonia3 štúdií
- Ann Arbor3 štúdií
- Canton3 štúdií
- Waterford3 štúdií
- Kalamazoo3 štúdií
Oficiálny text štúdie (anglicky)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- a 4 ďalších
Prebieha náborFáza 3
Vek 65 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- a 68 ďalších
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- a 43 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- The Cancer and Hematology Centers, Grand Rapids
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Karmanos Cancer Institute, Detroit
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Corewell Health the Michigan Cancer Consortium, Grand Rapids
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Karmanos Cancer Institute, Detroit
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Karmanos Cancer Center, Detroit
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07221500Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- West Michigan Cancer Center, Kalamazoo
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 5. 2026 · NCT02269592A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Henry Ford Hospital /ID# 270973, Detroit
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 4. 2026 · NCT06428019HPC Offered for PRESERVE Expansion
- Henry Ford Health, Detroit
Prebieha náborObservačná štúdia
Vek 12 až 80 · Všetky pohlavia · Aktualizované 28. 8. 2025 · NCT07145411Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.